

Steve Sisolak
Governor
Richard Whitley, MS
Director



DEPARTMENT OF
HEALTH AND HUMAN SERVICES
Division of Health Care Financing and Policy
Helping people. It's who we are and what we do.



Suzanne Bierman, JD, MPH
Administrator

NOTICE OF PUBLIC MEETING – SILVER STATE SCRIPTS BOARD

Date of Posting: August 10, 2020

Date of Meeting: Thursday, September 24, 2020 at 1:00 PM

Name of Organization: The State of Nevada, Department of Health and Human Services, Division of Health Care Financing and Policy (DHCFP), Silver State Script Board.

Place of Meeting: Please use the teleconference/WebEx options provided below. If accommodations are requested, please advise using the information at the end of this agenda. Out of deference to Declaration of Emergency Directive 006 (<https://nvhealthresponse.nv.gov/wp-content/uploads/2020/03/Declaration-of-Emergency-Directive-006-re-OML.3-21-20.pdf>) from the State of Nevada Executive Department signed by Governor Sisolak as well as Emergency Directive 003 (<https://nvhealthresponse.nv.gov/wp-content/uploads/2020/03/2020-03-20.Declaration-of-Emergency-Directive-003.pdf>) signed March 20, 2020, a physical location will not be open to the public for attendance at this time.

Webinar Registration: <https://optum.webex.com/optum/onstage/g.php?MTID=e3fc33f7df7b6ca737e3bcd6f0da541b0>

Or go to www.webex.com and enter the Event Number listed below.

Once you have registered for the meeting, you will receive an email message confirming your registration. This message will provide the information that you need to join the meeting.

Event Number: 161 321 3288

Click "Join Now"

Follow the instructions that appear on your screen to join the audio portion of the meeting. Audio will be transmitted over the internet.

A password should not be necessary, but if asked use: Medicaid1!

For Audio Only:

Phone: 1-763-957-6300

Event: 161 321 3288

[Please place your phone on mute unless providing public comment.]

Closed Executive Session - 1:00 PM

Open Session/Public Meeting - will begin Upon Completion of the Closed Executive Session

AGENDA

- 1. Call to Order and Roll Call**
- 2. Public Comment on Any Matter on the Agenda** *(Owing to the lack of a physical location for this meeting, public comment is encouraged to be submitted in advance so that it may be included in meeting materials and given attention. No action may be taken upon a matter raised through public comment unless the matter itself has been specifically included on an agenda as an action item. Please provide your name in any comment for record keeping purposes. You may submit comments in writing via e-mail to rxinfo@dncfp.nv.gov). There may be opportunity to take public comment via telephone but phone participants should disconnect their call and re-join if they must take another call. Do not place your phone on hold or you may disrupt the meeting for other participants. This guidance applies for all periods of public comment referenced further in the agenda, such as those related to clinical presentations.)*
- 3. Administrative**
 - a. **For Possible Action:** Review and Approve Meeting Minutes from June 25, 2020.
 - b. Status Update by the DHCFP.
- 4. Annual Review – Established Drug Classes Being Reviewed Due to the Release of New Drugs**
 - a. **For Possible Action:** Discussion and possible adoption of Biologic Response Modifiers, Immunomodulators, Targeted Immunomodulators, and Multiple Sclerosis Agents, Oral
 - i. Public comment.
 - ii. Drug class review presentation by OptumRx.
 - iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.
 - iv. Presentation of recommendations for PDL inclusion by OptumRx.
 - v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.
 - b. **For Possible Action:** Discussion and possible adoption of Cardiovascular Agents, Antihypertensive Agents, Calcium-Channel Blockers
 - i. Public comment.

- ii. Drug class review presentation by OptumRx.
 - iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.
 - iv. Presentation of recommendations for PDL inclusion by OptumRx.
 - v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.
- c. **For Possible Action:** Discussion and possible adoption of Dermatological Agents, Topical Anti-infectives, Acne Agents: Topical, Benzoyl Peroxide, Antibiotics and Combination Products
- i. Public comment.
 - ii. Drug class review presentation by OptumRx.
 - iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.
 - iv. Presentation of recommendations for PDL inclusion by OptumRx.
 - v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.
- d. **For Possible Action:** Discussion and possible adoption of Gastrointestinal Agents, Functional Gastrointestinal Disorder Drugs
- i. Public comment.
 - ii. Drug class review presentation by OptumRx.
 - iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.
 - iv. Presentation of recommendations for PDL inclusion by OptumRx.
 - v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.
- e. **For Possible Action:** Discussion and possible adoption of Hormones and Hormone Modifiers, Antidiabetic Agents, Insulins (Vials, Pens and Inhaled)
- i. Public comment.
 - ii. Drug class review presentation by OptumRx.
 - iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.
 - iv. Presentation of recommendations for PDL inclusion by OptumRx.
 - v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.
- f. **For Possible Action:** Discussion and possible adoption of Neurological Agents, Anticonvulsants, and Benzodiazepines
- i. Public comment.
 - ii. Drug class review presentation by OptumRx.
 - iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.
 - iv. Presentation of recommendations for PDL inclusion by OptumRx.

- v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.
- g. **For Possible Action:** Discussion and possible adoption of Ophthalmic Agents, Ophthalmic Anti-inflammatory Agents, Ophthalmic Corticosteroids
 - i. Public comment.
 - ii. Drug class review presentation by OptumRx.
 - iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.
 - iv. Presentation of recommendations for PDL inclusion by OptumRx.
 - v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.
- h. **For Possible Action:** Discussion and possible adoption of Respiratory Agents, Long-acting/Maintenance Therapy
 - i. Public comment.
 - ii. Drug class review presentation by OptumRx.
 - iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.
 - iv. Presentation of recommendations for PDL inclusion by OptumRx.
 - v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.

5. Annual Review - Established Drug Classes Being Reviewed Due to the Release of New Generics

- a. **For Possible Action:** Discussion and possible adoption of Anti-infective Agents, Cephalosporins, Third-Generation Cephalosporins
 - i. Public comment.
 - ii. Drug class review presentation by OptumRx.
 - iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.
 - iv. Presentation of recommendations for PDL inclusion by OptumRx.
 - v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.
- b. **For Possible Action:** Discussion and possible adoption of Cardiovascular Agents, Antihypertensive Agents, Vasodilators, Oral
 - i. Public comment.
 - ii. Drug class review presentation by OptumRx.
 - iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.
 - iv. Presentation of recommendations for PDL inclusion by OptumRx.
 - v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.

- c. **For Possible Action:** Discussion and possible adoption of Dermatological Agents, Topical Anti-infectives, Topical Antivirals
 - i. Public comment.
 - ii. Drug class review presentation by OptumRx.
 - iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.
 - iv. Presentation of recommendations for PDL inclusion by OptumRx.
 - v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.

- d. **For Possible Action:** Discussion and possible adoption of Electrolytic and Renal Agents, Phosphate Binding Agents
 - i. Public comment.
 - ii. Drug class review presentation by OptumRx.
 - iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.
 - iv. Presentation of recommendations for PDL inclusion by OptumRx.
 - v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.

- e. **For Possible Action:** Discussion and possible adoption of Genitourinary Agents, Benign Prostatic Hyperplasia (BPH) Agents, Alpha-Blockers and Bladder Antispasmodics
 - i. Public comment.
 - ii. Drug class review presentation by OptumRx.
 - iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.
 - iv. Presentation of recommendations for PDL inclusion by OptumRx.
 - v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.

- f. **For Possible Action:** Discussion and possible adoption of Musculoskeletal Agents, Anticancer Agents
 - i. Public comment.
 - ii. Drug class review presentation by OptumRx.
 - iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.
 - iv. Presentation of recommendations for PDL inclusion by OptumRx.
 - v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.

- g. **For Possible Action:** Discussion and possible adoption of Ophthalmic Agents, Ophthalmic Anti-infectives, Ophthalmic Quinolones
 - i. Public comment.
 - ii. Drug class review presentation by OptumRx.

- iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.
- iv. Presentation of recommendations for PDL inclusion by OptumRx.
- v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.

6. Annual Review – Established Drug Classes

- a. **For Possible Action:** Discussion and possible adoption of Antihistamines, H1 blockers, Non-Sedating H1 Blockers
 - i. Public comment.
 - ii. Drug class review presentation by OptumRx.
 - iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.
 - iv. Presentation of recommendations for PDL inclusion by OptumRx.
 - v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.

- b. **For Possible Action:** Discussion and possible adoption of Cardiovascular Agents, Antilipemics, Cholesterol Absorption Inhibitors, and HMG-CoA Reductase Inhibitors (Statins)
 - i. Public comment.
 - ii. Drug class review presentation by OptumRx.
 - iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.
 - iv. Presentation of recommendations for PDL inclusion by OptumRx.
 - v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.

- c. **For Possible Action:** Discussion and possible adoption of Dermatological Agents, Topical Antineoplastics, Topical Retinoids
 - i. Public comment.
 - ii. Drug class review presentation by OptumRx.
 - iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.
 - iv. Presentation of recommendations for PDL inclusion by OptumRx.
 - v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.

- d. **For Possible Action:** Discussion and possible adoption of Gastrointestinal Agents, Antiemetics, Pregnancy-induced Nausea and Vomiting Treatment, and Gastrointestinal Anti-inflammatory Agents
 - i. Public comment.
 - ii. Drug class review presentation by OptumRx.

- iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.
 - iv. Presentation of recommendations for PDL inclusion by OptumRx.
 - v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.
- e. **For Possible Action:** Discussion and possible adoption of Hematological Agents, Platelet Inhibitors
- i. Public comment.
 - ii. Drug class review presentation by OptumRx.
 - iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.
 - iv. Presentation of recommendations for PDL inclusion by OptumRx.
 - v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.
- f. **For Possible Action:** Discussion and possible adoption of Hormones and Hormone Modifiers, Antidiabetic Agents, Incretin Mimetics; Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors
- i. Public comment.
 - ii. Drug class review presentation by OptumRx.
 - iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.
 - iv. Presentation of recommendations for PDL inclusion by OptumRx.
 - v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.
- g. **For Possible Action:** Discussion and possible adoption of Monoclonal Antibodies for the treatment of Respiratory Conditions
- i. Public comment.
 - ii. Drug class review presentation by OptumRx.
 - iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.
 - iv. Presentation of recommendations for PDL inclusion by OptumRx.
 - v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.
- h. **For Possible Action:** Discussion and possible adoption of Musculoskeletal Agents, Restless Leg Syndrome Agents
- i. Public comment.
 - ii. Drug class review presentation by OptumRx.
 - iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.
 - iv. Presentation of recommendations for PDL inclusion by OptumRx.

- v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.
- i. **For Possible Action:** Discussion and possible adoption of Psychotropic Agents, ADHD Agents
 - i. Public comment.
 - ii. Drug class review presentation by OptumRx.
 - iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.
 - iv. Presentation of recommendations for PDL inclusion by OptumRx.
 - v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.
- j. **For Possible Action:** Discussion and possible adoption of Respiratory Agents, Short-Acting/Rescue Therapy
 - i. Public comment.
 - ii. Drug class review presentation by OptumRx.
 - iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.
 - iv. Presentation of recommendations for PDL inclusion by OptumRx.
 - v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.
- k. **For Possible Action:** Discussion and possible adoption of Toxicology Agents, Substance Abuse Agents
 - i. Public comment.
 - ii. Drug class review presentation by OptumRx.
 - iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.
 - iv. Presentation of recommendations for PDL inclusion by OptumRx.
 - v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.

7. Annual Review – Drug Classes Without Proposed Changes

- a. Public Comment
- b. **For Possible Action:** Discussion and possible adoption of the Preferred Drug List (PDL) as presented by OptumRx and the Division of Health Care Financing and Policy without changes.
 - i. Analgesics, Analgesic/Miscellaneous, Neuropathic Pain/Fibromyalgia Agents; Tramadol and Related Drugs; Opiate Agonists; Opiate Agonists - Abuse Deterrent; Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) - Oral
 - ii. Anti-infective Agents, Aminoglycosides, Inhaled Aminoglycosides; Antivirals, Alpha Interferons; Antivirals, Anti-hepatitis Agents, Polymerase Inhibitors/Combination Products; Ribavirins; Anti-Herpetic Agents; Influenza

- Agents; Cephalosporins, Second-Generation Cephalosporins; Macrolides; Quinolones, Quinolones - 2nd Generation; Quinolones - 3rd Generation;
- iii. Autonomic Agents, Sympathomimetics, Self-Injectable Epinephrine
- iv. Biologic Response Modifiers, Multiple Sclerosis Agents, Injectable; Specific Symptomatic Treatment
- v. Cardiovascular Agents, Antihypertensive Agents, Angiotensin II Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors); Beta-Blockers; Vasodilators, Inhaled; Antilipemics, Bile Acid Sequestrants; Fibrin Acid Derivatives; Niacin Agents; Omega-3 Fatty Acids
- vi. Dermatological Agents, Antipsoriatic Agents; Topical Analgesics; Topical Anti-infectives, Impetigo Agents: Topical; Topical Scabicides; Topical Anti-inflammatory Agents, Immunomodulators: Topical;
- vii. Gastrointestinal Agents, Antiemetics, Serotonin-receptor antagonists/Combo; Antiulcer Agents, H2 blockers; Proton Pump Inhibitors (PPIs); Gastrointestinal Enzymes
- viii. Genitourinary Agents, Benign Prostatic Hyperplasia (BPH) Agents, 5-Alpha Reductase Inhibitors
- ix. Hematological Agents, Anticoagulants, Oral; Injectable; Erythropoiesis-Stimulating Agents
- x. Hormones and Hormone Modifiers, Androgens; Antidiabetic Agents, Alpha-Glucosidase Inhibitors/Amylin analogs/Misc.; Biguanides; Dipeptidyl Peptidase-4 Inhibitors; Meglitinides; Sulfonylureas; Thiazolidinediones; Anti-hypoglycemic Agents; Pituitary Hormones, Growth hormone modifiers; Progestins for Cachexia
- xi. Musculoskeletal Agents, Bone Resorption Inhibitors, Bisphosphonates; Nasal Calcitonins; Skeletal Muscle Relaxants
- xii. Neurological Agents, Alzheimer's Agents; Anticonvulsants, Barbiturates; Hydantoins; Anti-Migraine Agents, Calcitonin Gene-Related Peptide (CGRP) Receptor Antagonists; Anti-Migraine Agents, Serotonin-Receptor Agonists; Antiparkinsonian Agents, Dopamine Precursors; Antiparkinsonian Agents, Non-ergot Dopamine Agonists
- xiii. Ophthalmic Agents, Antiglaucoma Agents; Ophthalmic Antihistamines; Ophthalmic Anti-infectives, Ophthalmic Macrolides; Ophthalmic Anti-infective/Anti-inflammatory Combinations; Ophthalmic Anti-inflammatory Agents, Ophthalmic Nonsteroidal Anti-inflammatory Drugs (NSAIDs); Ophthalmics for Dry Eye Disease
- xiv. Otic Agents, Otic Anti-infectives, Otic Quinolones
- xv. Psychotropic Agents, Antidepressants, Other; Selective Serotonin Reuptake Inhibitors (SSRIs); Antipsychotics, Atypical Antipsychotics – Oral and Topical; Long-acting Injectable; Anxiolytics, Sedatives, and Hypnotics; Psychostimulants, Narcolepsy Agents
- xvi. Respiratory Agents, Nasal Antihistamines; Respiratory Anti-inflammatory Agents, Leukotriene Receptor Antagonists; Nasal Corticosteroids; Phosphodiesterase Type 4 Inhibitors;
- xvii. Toxicology Agents, Antidotes, Opiate Antagonists

8. OptumRx Reports: New Drugs to Market and New Line Extensions

9. Closing Discussion

- a. Public comments on any subject. *(Owing to the lack of a physical location for this meeting, public comment is encouraged to be submitted in advance so that it may be included in meeting materials and given attention. No action may be taken upon a matter raised through public comment unless the matter itself has been specifically included on an agenda as an action item. Please provide your name in any comment for record keeping purposes. You may submit comments in writing via e-mail to (rxinfo@dncfp.nv.gov). There may be opportunity to take public comment via telephone, but phone participants should disconnect their call and re-join if they must take another call. Do not place your phone on hold or you may disrupt the meeting for other participants. Public comments may be related to topics on the agenda or matters related to other topics per NRS 241.020(3)(3)(II).)*
- b. Date and location of the next meeting.
 - i. Discussion of the time of the next meeting.
- c. Adjournment.

PLEASE NOTE: Items may be taken out of order at the discretion of the chairperson. Items may be combined for consideration by the public body. Items may be pulled or removed from the agenda at any time. If an action item is not completed within the time frame that has been allotted, that action item will be continued at a future time designated and announced at this meeting by the chairperson. All public comment may be limited to 3 minutes and written comments are encouraged if possible.

This notice and agenda have been posted online at <http://dncfp.nv.gov> and <http://notice.nv.gov> as well as Carson City, Las Vegas, and Reno central offices for the Division of Health Care Financing and Policy. E-mail notice has been made to such individuals as have requested notice of meetings (to request notifications please contact tbenitez@dncfp.nv.gov, or at 1100 East William Street, Suite 101, Carson City, Nevada 89701 or call Tanya Benitez at (775) 684-3730). At this time, in deference to Emergency Directive 006 dated March 22, 2020 and related directives which have discouraged certain in-person activities, notice has not been posted at other physical locations.

If you require a physical copy of supporting material for the public meeting, please contact tbenitez@dncfp.nv.gov, or at 1100 East William Street, Suite 101, Carson City, Nevada 89701 or call Tanya Benitez at (775) 684-3730. Supporting material will also be posted online as referenced above.

All persons that have requested in writing to receive the Public Hearings agenda have been duly notified by mail or e-mail.

Note: We are pleased to make reasonable accommodations for members of the public with a disability and wish to participate. If accommodated arrangements are necessary, notify the Division of Health Care Financing and Policy as soon as possible and at least ten days in advance of the meeting, by e-mail at tbenitez@dncfp.nv.gov in writing, at 1100 East William Street, Suite 101, Carson City, Nevada 89701 or call Tanya Benitez at (775) 684-3730.

August 10, 2020

Page 11

Per Nevada Governor Sisolak's Declaration of Emergency Directive 006; Subsection 3: The requirements contained in NRS 241.020 (4) (a) that public notice agendas be posted at physical locations within the State of Nevada are suspended.

Per Nevada Governor Sisolak's Declaration of Emergency Directive 006; Subsection 4: Public bodies must still comply with requirements in NRS 241.020 (4)(b) and NRS 241.020 (4)(c) that public notice agendas be posted to Nevada's notice website and the public body's website, if it maintains one along with providing a copy to any person who has requested one via U.S. mail or electronic mail.

Per Nevada Governor Sisolak's Declaration of Emergency Directive 006; Subsection 5: The requirement contained in NRS 241.020 (3)(c) that physical locations be available for the public to receive supporting material for public meetings is suspended.

Per Nevada Governor Sisolak's Declaration of Emergency Directive 006; Subsection 6: If a public body holds a meeting and does not provide a physical location where supporting material is available to the public, the public body must provide on its public notice agenda the name and contact information for the person designated by the public body from whom a member of the public may request supporting material electronically and must post supporting material to the public body's website, if it maintains one.